DOTA, or 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (CAS 60239-18-1), is a highly significant molecule in the fields of medical imaging and targeted therapeutics. Its unique macrocyclic structure and robust chelating capabilities make it a preferred choice for complexing metal ions used in diagnostic and therapeutic applications. Understanding its properties and sourcing reliable material is crucial for any researcher or manufacturer in this domain.

Chemically, DOTA is characterized by its molecular formula C16H28N4O8 and a molecular weight of approximately 404.42. It typically presents as a white solid. The key feature of DOTA is its ability to form exceptionally stable complexes with a variety of metal ions, including lanthanides like Gadolinium (Gd3+) for MRI contrast agents, and various radionuclides such as Yttrium-90 (90Y) and Lutetium-177 (177Lu) for radiopharmaceutical applications. This high stability prevents the premature release of potentially toxic metal ions, ensuring patient safety and diagnostic accuracy.

NINGBO INNO PHARMCHEM CO.,LTD. is a prominent manufacturer and supplier of DOTA, offering this vital pharmaceutical intermediate with a guaranteed purity of 98%min. We are dedicated to providing consistent quality and reliable supply to our global clientele. Our manufacturing processes adhere to strict quality control measures, ensuring that the DOTA you purchase is suitable for demanding pharmaceutical and research applications. As a leading supplier in China, we aim to provide competitive pricing and efficient service, making it easier for you to buy DOTA for your innovative projects.

The applications of DOTA are diverse, ranging from enhancing MRI scans to enabling precise delivery of therapeutic radioisotopes in cancer treatment. Its versatility also extends to other diagnostic modalities. For reliable sourcing and high-quality DOTA, NINGBO INNO PHARMCHEM is your trusted partner. We encourage you to reach out to us for inquiries regarding specifications, pricing, and bulk purchase options.